J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?

J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Protagonist (PTGX) Earnings Call Transcript

Well, that's a very important question and distinction and I would have our CMO, Sam, take a crack at it. Samuel Saks: Yes. I ...